David Roth - 12 Dec 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Chief Medical Officer
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol: SYRS
Transactions as of: 12 Dec 2023
Net transactions value: -$31,121
Form type: 4
Filing time: 14 Dec 2023, 16:24:05 UTC
Previous filing: 08 Dec 2023
Next filing: 02 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Sale	$31,121	-6,287	-100%	$4.95	0	12 Dec 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.